Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.43 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 5/20 | 0.39 |
| ▸ | METAP1 | P53582 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethionine SCHEMBL7073863 | 0.81 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL8967 | 0.81 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL8966 | 0.81 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL9419884 | 0.80 | BHMT (0.58) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL28999714 | 0.79 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL11572299 | 0.79 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL31567824 | 0.79 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL29359945 | 0.79 | BHMT (0.43) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL28989455 | 0.79 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL3348592 | 0.79 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-117510989-A | Method for oxidizing graphene sulfonate flame retardant | 中原工学院 | 2024-02-06 | — | — | CN | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| EP-3828173-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4017852-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | BHMT 2185/4885BHMT2 3505/4885NOS2 1549/4885 |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | BHMT 2259/4885BHMT2 3586/4885NOS2 1294/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | BHMT 2259/4885BHMT2 3586/4885NOS2 1294/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | BHMT 2259/4885BHMT2 3586/4885NOS2 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.